Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole in Schizophrenia and Substance Use Disorder
NCT03526354Phase 4Completed
- Sponsor
- University of Massachusetts
- Start
- Jun 2018
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of brexpiprazole in schizophrenia, schizoaffective disorder and substance use disorder (SUD), sponsored by University of Massachusetts. Primary endpoint: Timeline Follow Back at 12 weeks. Started Jun 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophreniaschizoaffective disordersubstance use disorder (SUD)
Beyond the preview
Go deeper on NCT03526354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526354.